Alaunos Therapeutics Inc TCRT

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders.

The label

Markdown

read at $2.05

Alaunos Therapeutics Inc holds its Markdown at $2.05.

PHPhase · the trend structure carries the Markdown label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate

edge confirmed
edge broken
edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2026-07-19
Phase	Markdown · caution
Quantitative state	Consolidating, no directional conviction, held for 144 days
Price	$2.05
Valuation	N/A trailing · -3.42 forward price to earnings
Values screen	PASS · score 70.0
Beta	-1.02

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Forward P/E	-3.4x
Profit margin	0.0% currently unprofitable
Return on equity	-350.3% not currently earning a positive return on equity
Current ratio	1.63 healthy short-term liquidity
Beta	-1.02 barely tracks the market's swings
Market cap	$5M
Employees	1

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in TCRT's space worth a look

GOVX Geovax Labs Inc CDIO Cardio Diagnostics Holdings Inc ELAB PMGC Holdings Inc BGMS Bio Green Med Solution Inc MBIO Mustang Bio Inc MLEC Moolec Science SA

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 25%. Entered 2026-07-18 · Accumulation

The dated journal · newest first, never edited

2026-07-18 Accumulation $2.26 +0.0% Entry 3

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 25%.

2026-07-03 Accumulation $2.26 +0.0% Entry 2

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-02 Accumulation $2.26 Entry 1

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
Period	Price then	Price return	Divs per share	$1,000 became	Total return
1 month	$2.63	-24.0%	·	$761	-24.0%
2 months	$2.89	-30.8%	·	$692	-30.8%
3 months	$3.19	-37.3%	·	$627	-37.3%
6 months	$4.27	-53.2%	·	$468	-53.2%
1 year	$3.24	-38.3%	·	$617	-38.3%
2 years	$10.40	-80.8%	·	$192	-80.8%
3 years	$69.00	-97.1%	·	$29	-97.1%
5 years	$432.00	-99.5%	·	$5	-99.5%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever TCRT does next, these words stay.

Alaunos Therapeutics Inc · TCRT · Markdown · $2.05
Recorded 2026-07-19 · before the outcome · scored mechanically

All of today's entries See the running score

Alaunos Therapeutics Inc TCRT

This entry now belongs to the ledger. Whatever TCRT does next, these words stay.

Before you go